Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Expert Illustrations and Commentaries: Translating Advances in XLH and TIO Into Practical Strategies for Management

Access Activity

Overview / Abstract:

Target Audience

This educational activity is directed primarily toward endocrinologists, rheumatologists, nephrologists, pediatricians, primary care providers, geneticists, nurse practitioners, and physician assistants. The secondary target audience includes pharmacists, managed care professionals, neurologists, orthopedists, radiologists, fellows and other health care professionals involved in the care of patients with XLH or TIO.

Activity Overview

As chronic diseases, X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) have a debilitating impact on the quality of life of affected patients. In XLH, significant complications result from unresolved symptoms in childhood, as well as from disease progression. In TIO, difficulties locating or resecting the causative tumor can result in lifelong morbidity. Unfortunately, knowledge of these conditions is also limited, and many patients experience delayed diagnoses and ineffective treatment.

This activity provides clinicians with a deeper understanding of XLH and TIO in terms of the pathophysiology and clinical presentation so they can better manage patients. In this activity, the faculty describe available novel therapies and their unique mechanisms in order to better select treatments for patients. They also explain the mechanism of action of novel therapies for XLH and TIO. In addition, a white board animation helps to illustrate this for participants.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the pathophysiological basis for the development of symptoms in patients with XLH or TIO
Identify clinical presentations of XLH and TIO that warrant further investigation and diagnostic testing
Discuss the mechanisms of action for novel and emerging therapies in the management of patients with XLH or TIO
Apply traditional and emerging therapeutic approaches toward the development of management plans for patients with XLH or TIO

Expiration

Jan 20, 2022

Discipline(s)

Nursing CNE, Physician CME

Format

Online

Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Thomas O. Carpenter, MD
Professor of Pediatrics (Endocrinology)
Professor of Orthopedics and Rehabilitation
Yale University School of Medicine
New Haven, CT

FACULTY_NAME
Peter Tebben, MD
Mayo Clinic
Departments of Internal Medicine and Pediatrics
Division of Endocrinology
Rochester, MN

Sponsors / Supporters / Grant Providers

Ultragenyx Pharmaceutical Inc.

Keywords / Search Terms

Relias LLC Relias LLC., FREE CME., XLH ,TIO Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map